PVT 401
Alternative Names: PVT-401Latest Information Update: 18 Sep 2023
At a glance
- Originator Parvus Therapeutics
- Class Anti-inflammatories; Peptides
- Mechanism of Action Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases
Most Recent Events
- 05 Sep 2023 Preclinical studies in Inflammatory bowel diseases in USA, prior to September 2023 (unspecified route) (Parvus therapeutic pipeline, September 2023)
- 16 May 2019 Parvus therapeutics enters into a worldwide collaboration and license agreement with Genentech for Navacim™ therapeutics for Autoimmune diseases
- 16 May 2019 Parvus therapeutics and Genentech plans for clinical trial of PVT 401